Ad Law Access
FDA Turns Up the Heat on GLP 1 Dupes Sold “For Research Use Only,” Finds Intended Use Suggests Otherwise
Consumer demand for GLP‑1 drugs such as Ozempic and Zepbound continues to surge, fueling rapid growth in the market for GLP-1 drugs and compounded GLP-1 products, as well as supplements that are marketed to have…
IAPP Global Privacy Summit 2026: State AI Trends, FTC Signals, California’s DROP Build-Out, and the Hard Work of Cookie Compliance
Conference season is upon us, and with the cherry blossoms at peak bloom, the IAPP held its annual Global Privacy Summit here in Washington. The Summit featured keynotes from Prince Harry and Salman Rushdie, both of…
NAD Decision Provides Guidance on Substantiating AI Claims
At last year’s ANA Masters of Advertising Law Conference, Phyllis Marcus, Vice President of NAD, stated that NAD would closely scrutinize claims related to AI and hinted that new decisions were on the way. We wrote…
Washington Amends State Anti-Spam Law
Last year, the Washington Supreme Court issued a significant decision in a class action lawsuit accusing Old Navy of sending emails that included false or misleading information about the duration of sales. The Court…
From MAHA to Market: FDA and Some Retailers Announcing New Policies on Colors
The Make America Healthy Again (MAHA) movement has already prompted notable changes in federal and state food policy and has prompted regulators, plaintiff’s lawyers, manufacturers, retailers, and consumers to take a…